REG - Oncimmune Hldgs PLC - Grant of Options and PDMR Dealing

Oncimmune HoldingsAnnouncement

13/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220713:nRSM2466Sa&default-theme=true

RNS Number : 2466S  Oncimmune Holdings PLC  13 July 2022

13 July 2022

 

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Grant of Options and PDMR Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, today announces that options to subscribe for ordinary shares of £0.01
each in the Company ("Ordinary Shares") have been granted to Alistair
Macdonald following his appointment as the Company's Non-executive Chair on 8
July 2022.

 

Alistair Macdonald has been granted 127,389 options at an exercise price of
£0.785 per Ordinary Share and 492,252 options (the "Scheme Options") at an
exercise price of £0.01 per Ordinary Share pursuant to the incentivisation
scheme established for members of senior management in September 2020 (the
"Scheme"). The Scheme Options will vest based on the performance of the
Company's share price over the course of the three years from the
establishment of the Scheme, between £2.00 and £3.50 ("Target Share Price")
(as set out below), which must be achieved for 20 consecutive business days or
on certain trigger event.  This vesting mechanism is directly aligned with
the delivery of shareholder value. Once vested, Options (or resulting shares)
must be held for a further two years, subject to certain exceptions and
acceleration events. The Target Share Prices and associated vesting levels for
Alistair Macdonald's Scheme Options are as follows:

 

 Target Share Price
 £2.00    £2.50    £2.75    £3.00    £3.50
 Percentage of Award Vesting
 25%      50%      62.5%    75%      100%
 Total Number of Options Vesting
 123,063  246,126  307,658  369,189  492,252

 

The Scheme Options granted to Alistair Macdonald replace the unvested options
granted to former Chair Meinhard Schmidt in September 2020, which have now
lapsed following Meinhard's retirement from the Board.

 

This announcement, including the notification below, is made in accordance
with the requirements of the UK Market Abuse Regulation and serves as
notification and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMR") and persons closely associated with them.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Alistair Macdonald

 2    Reason for the notification

 a)   Position/status                                              Non-executive Chair

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Oncimmune Holdings plc

 b)   LEI                                                          213800HCYIWT6YPI1I02

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of £0.01 each

      Identification code                                          ISIN: GB00BYQ94H38

 b)   Nature of the transaction                                    1) Grant of options

                                                                   2) Grant of Scheme Options

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     1) £0.785         127,389
                                                                                     2) £0.01          492,252

 d)   Aggregated information                                       N/A - single transactions

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      12 July 2022

 f)   Place of the transaction                                     Outside a trading venue

 

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

 

Media enquiries:

John Goold

IR@oncimmune.com

 

About Oncimmune

 

ImmunoINSIGHTS Service Business

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organizations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research centre in Dortmund, Germany. The business platform enables
life science organizations to optimize drug development and delivery, leading
to more effectively targeted and safer treatments for patients.

 

The ImmunoINSIGHTS development team is based in the US and Europe and
Oncimmune is seeking to replicate the Dortmund facility in the US in the
medium term.

 

EarlyCDT Product Business

 

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard clinical
diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market
estimated to grow to £3.8bn by 2024. With over 200,000 tests already
performed for patients worldwide and its use being supported by peer reviewed
data in over 12,000 patients, we are poised to become an integral component of
future lung cancer detection programs, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

What is SeroTag(TM)?

 

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our
ImmunoINSIGHTS services to discover and validate novel biomarkers can help
stratify patients in multiple cancer indications and with different autoimmune
diseases.

 

This high-throughput, multiplex technology is based on one of the largest,
in-house protein libraries, as well as a unique, ever-growing repository of
disease data for indications including, but not limited to, autoimmune
diseases and cancer. As a result, SeroTag is helping to address and monitor a
number of challenges currently hindering the successful development and
broader application of both cancer immunotherapies and treatments for
autoimmune diseases.

 

The platform is being applied to discover and validate biomarkers and develop
precision diagnostic tools from minimally invasive liquid biopsies. SeroTag
analyses autoantibodies-some of the most stable analytes-and is used most
frequently for the identification of IgG isoforms, in addition to IgM and IgA,
from just a few drops of serum.

 

The SeroTag platform acts as the primary discovery engine that feeds into the
creation of Oncimmune's NavigAID(TM) disease-specific stratification panels.
These precision medicine tools which are enabling patient and disease
stratification and support therapeutic development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBKBBBFBKDDOD